Your browser doesn't support javascript.
loading
Anti-Postmenopausal osteoporosis effects of Isopsoralen: A bioinformatics-integrated experimental study.
Li, Hao; Wang, Changyuan; Jin, Yue; Cai, Yuanqing; Yao, Jialin; Meng, Qiang; Wu, Jingjing; Wang, Huihan; Sun, Huijun; Liu, Mozhen.
Afiliación
  • Li H; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Wang C; Academy of Integrative Medicine, Dalian Medical University, Dalian, China.
  • Jin Y; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Cai Y; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Yao J; Department of Orthopaedics, the First Affiliated Hospital, Dalian Medical University, Dalian, China.
  • Meng Q; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Wu J; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Wang H; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Sun H; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
  • Liu M; Department of Clinical Pharmacology, College of Pharmacy, Dalian Medical University, Dalian, China.
Phytother Res ; 37(1): 231-251, 2023 Jan.
Article en En | MEDLINE | ID: mdl-36123318
ABSTRACT
Isopsoralen (IPRN), which comes from the fruit of Psoralea corylifolia, has been identified as a kind of phytoestrogen and has been proven to be effective for the treatment of osteoporosis (OP). However, the mechanisms underlying IPRN's anti-OP effects, especially the anti-postmenopausal osteoporosis (PMOP) effects, remain indistinct. Thus, this study aimed to investigate the effects and mechanisms of IPRN's anti-PMOP activity. In this study, the bioinformatics results predicted that IPRN could resist PMOP by targeting EGFR, AKT1, SRC, CCND1, ESR1 (ER-α), AR, PGR, BRCA1, PTGS2, and IGF1R. An ovariectomized (OVX) mice model and a H2 O2 -induced bone marrow mesenchyml stem cells (BMSCs) model confirmed that IPRN could inhibit the bone loss induced by OVX in mice and promote the osteogenic differentiation in H2 O2 -induced BMSCs by inhibiting oxidative stress and apoptosis. Moreover, IPRN could significantly produce the above effects by upregulating ESR1. IPRN might be a therapeutic agent for PMOP by acting as an estrogen replacement agent and a natural antioxidant.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteoporosis / Osteoporosis Posmenopáusica / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Phytother Res Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Osteoporosis / Osteoporosis Posmenopáusica / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Phytother Res Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2023 Tipo del documento: Article País de afiliación: China